We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vectron Biosolutions Obtains Strong Results for Biosimilar Production
Product News

Vectron Biosolutions Obtains Strong Results for Biosimilar Production

Vectron Biosolutions Obtains Strong Results for Biosimilar Production
Product News

Vectron Biosolutions Obtains Strong Results for Biosimilar Production


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Vectron Biosolutions Obtains Strong Results for Biosimilar Production"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vectron Biosolutions has announced that they have obtained strong results for manufacture of selected biosimilar proteins using their proprietary E. coli expression technology.

The study was done side-by-side with other expression technologies and Vectron’s technology gave higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins.

The increase in yield was 2 to 25 times compared to the best conventional technology.

The biosimilar proteins that were produced more efficiently with Vectron’s technology than with other technologies were human growth hormone, interferon β-1b, TNF α-1a, IGF-1, insulin, IL-2, and IL-1RA.

“Demonstrating that our technology is superior for manufacture of many valuable therapeutic proteins is a major milestone for us,” commented CEO in Vectron Biosolutions AS, Trond Erik Vee Aune.

Vee Aune continued, “Significant increases in soluble and insoluble yields translate directly to large savings in cost of goods for our pharmaceutical partners, especially in the highly competitive biosimilars market where cost-efficient manufacturing processes are essential. In addition, demonstrating that our technology can be used to obtain many-fold higher titers means that our services and technology is highly suitable for new therapeutic proteins being developed, especially those where low solubility and/or low yields are a complicating issue.”

Advertisement